(Q34877827)

5 August 2017

1 reference

title

The role of combination medical therapy in benign prostatic hyperplasia (English)

1 reference

5 August 2017

K A Greco

1

1 reference

5 August 2017

K T McVary

series ordinal

2

1 reference

5 August 2017

publication date

1 December 2008

1 reference

International Journal of Impotence Research

5 August 2017

published in

1 reference

5 August 2017

volume

20 Suppl 3

1 reference

5 August 2017

page(s)

S33-43

1 reference

Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

A review of combination therapy in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Benign prostatic hyperplasia. Part 1--diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

The development of human benign prostatic hyperplasia with age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Incidence rates and risk factors for acute urinary retention: the health professionals followup study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.51

7 January 2021

Identifiers

DOI

10.1038/IJIR.2008.51

1 reference

Dimensions Publication ID

5 August 2017

1021894148

0 references

1 reference